ACAM-FLU-A

WikiDoc Resources for ACAM-FLU-A
Articles
Most recent articles on ACAM-FLU-A Most cited articles on ACAM-FLU-A Review articles on ACAM-FLU-A Articles on ACAM-FLU-A in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on ACAM-FLU-A Images of ACAM-FLU-A Photos of ACAM-FLU-A Podcasts & MP3s on ACAM-FLU-A Videos on ACAM-FLU-A
Evidence Based Medicine
Cochrane Collaboration on ACAM-FLU-A Bandolier on ACAM-FLU-A TRIP on ACAM-FLU-A
Clinical Trials
Ongoing Trials on ACAM-FLU-A at Clinical Trials.gov Trial results on ACAM-FLU-A Clinical Trials on ACAM-FLU-A at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on ACAM-FLU-A NICE Guidance on ACAM-FLU-A NHS PRODIGY Guidance FDA on ACAM-FLU-A CDC on ACAM-FLU-A
Books
Books on ACAM-FLU-A
News
ACAM-FLU-A in the news Be alerted to news on ACAM-FLU-A News trends on ACAM-FLU-A
Commentary
Blogs on ACAM-FLU-A
Definitions
Definitions of ACAM-FLU-A
Patient Resources / Community
Patient resources on ACAM-FLU-A Discussion groups on ACAM-FLU-A Patient Handouts on ACAM-FLU-A Directions to Hospitals Treating ACAM-FLU-A Risk calculators and risk factors for ACAM-FLU-A
Healthcare Provider Resources
Symptoms of ACAM-FLU-A Causes & Risk Factors for ACAM-FLU-A Diagnostic studies for ACAM-FLU-A Treatment of ACAM-FLU-A
Continuing Medical Education (CME)
CME Programs on ACAM-FLU-A
International
ACAM-FLU-A en Espanol ACAM-FLU-A en Francais
Business
ACAM-FLU-A in the Marketplace Patents on ACAM-FLU-A
Experimental / Informatics
List of terms related to ACAM-FLU-A

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

ACAM-FLU-A is a vaccine, being developed by Acambis, which is intended to provide lifelong protection against all strains of Influenza A. The vaccine targets the M2 protein which is found on the surface of all strains of Influenza A.

The vaccine has been tested in a human trial, in the United States, where it is claimed to have successfully protected 90% of individuals against the flu virus. Further human trials are planned.